Table 2.

Patient Characteristics (N=133)

Age: median (range)	41 (18–65)
Gender: Male / female	77 / 56
Hodgkin’s lymphoma (N=80)
Primary refractory	53
Relapsed	27
Remission ≤1 yr	72 (90%)
Extranodal disease at relapse/PD	40 (50%)
B symptoms at relapse/PD	11 (14%)
No. clinical risk factors (*)
1	20 (25%)
2	43 (56%)
3	17 (21%)
No. prior relapses/PD:
1	46 (57%)
>1	34 (43%)
Bulky tumor at relapse/PD	29 (36%)
Prior treatment
No. prior chemotherapy regimens: median (range)	3 (2–6)
Prior radiotherapy	22
Disease status at HDC
Clinical response: CR / PR / PD	39 / 18 / 23
PET: Positive / Negative	41 / 39
NHL (N=46)
B-LCL	30
Primary DLCL	18
Transformed	4
Primary CNS LCL	4
Primary mediastinal LCL	4
Burkitt’s lymphoma	3
Follicular lymphoma	2
T-NHL	11
Anaplastic large cell	6
Peripheral TCL NOS	2
NK/T	2
Angioimmunoblastic	1
Primary refractory (B-LCL / FL / BL / T-NHL)	21
Relapsed (B-LCL / FL / BL / T-NHL)	25
Time to relapse
≤12 months	19
>12 months	6
No. prior relapses/PD:
1	23
>1	23
Secondary IPI (**)
0–1	7 (17%)
2–3	25 (62%)
>3	8 (20%)
Elevated LDH at relapse/PD	13
Prior treatment
No. prior chemotherapy regimens: median (range)	3 (2–9)
Prior radiotherapy	10
Disease status at HDC
Clinical status: CR / PR / PD	21 / 14 / 11
PET status : Positive / Negative	23 / 23
Myeloma (N=7)
Primary refractory	4
Relapsed and refractory	3
No. prior relapses relapses/PD:
1	3
>1	4
Stage III	7
Poor-prognosis cytogenetic abnormalities (CGA) (**)	3
Prior treatment
No. prior chemotherapy regimens: median (range)	3 (2–5)
Prior radiotherapy	3
Disease status at HDC
Clinical status: CR / PR / PD	0 / 2 / 5

^(*)Risk factors: B symptoms at relapse, extranodal disease (both at relapse), or remission duration <1 year.

^(**)Poor-prognosis CGA: 17p deletion, t(14;16), t(4;14) and 13 deletion.